Celldex Therapeutics Analyst Ratings
Celldex Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/12/2023 | 96.72% | Cantor Fitzgerald | → $54 | Reiterates | Overweight → Overweight |
| 09/27/2023 | 96.72% | Cantor Fitzgerald | → $54 | Reiterates | Overweight → Overweight |
| 08/22/2023 | -23.5% | Wells Fargo | → $21 | Initiates Coverage On | → Underweight |
| 08/16/2023 | 96.72% | Cantor Fitzgerald | → $54 | Reiterates | Overweight → Overweight |
| 08/10/2023 | 165.94% | HC Wainwright & Co. | → $73 | Reiterates | Buy → Buy |
| 08/09/2023 | 165.94% | HC Wainwright & Co. | → $73 | Reiterates | Buy → Buy |
| 06/12/2023 | 165.94% | HC Wainwright & Co. | → $73 | Reiterates | Buy → Buy |
| 05/31/2023 | 165.94% | HC Wainwright & Co. | → $73 | Reiterates | → Buy |
| 05/05/2023 | 96.72% | Cantor Fitzgerald | $55 → $54 | Maintains | Overweight |
| 05/05/2023 | 165.94% | HC Wainwright & Co. | → $73 | Reiterates | → Buy |
| 03/22/2023 | 165.94% | HC Wainwright & Co. | → $73 | Reiterates | → Buy |
| 03/01/2023 | 165.94% | HC Wainwright & Co. | → $73 | Reiterates | → Buy |
| 02/27/2023 | 165.94% | HC Wainwright & Co. | → $73 | Reiterates | → Buy |
| 11/11/2022 | 129.51% | Guggenheim | $68 → $63 | Maintains | Buy |
| 08/09/2022 | 133.15% | SVB Leerink | $68 → $64 | Maintains | Outperform |
| 07/01/2022 | 165.94% | HC Wainwright & Co. | $60 → $73 | Maintains | Buy |
| 09/17/2021 | 140.44% | Jefferies | → $66 | Initiates Coverage On | → Buy |
| 09/13/2021 | 118.58% | HC Wainwright & Co. | $54 → $60 | Maintains | Buy |
| 09/10/2021 | 147.72% | SVB Leerink | → $68 | Initiates Coverage On | → Outperform |
| 08/06/2021 | 96.72% | HC Wainwright & Co. | $50 → $54 | Maintains | Buy |
| 07/22/2021 | 140.44% | Guggenheim | → $66 | Initiates Coverage On | → Buy |
| 07/12/2021 | 82.15% | HC Wainwright & Co. | $36 → $50 | Maintains | Buy |
| 02/23/2021 | 31.15% | HC Wainwright & Co. | $25 → $36 | Maintains | Buy |
| 10/19/2020 | -8.93% | HC Wainwright & Co. | $16 → $25 | Maintains | Buy |
| 03/27/2020 | -41.71% | HC Wainwright & Co. | $19 → $16 | Reiterates | → Buy |
| 02/21/2020 | -70.86% | Cantor Fitzgerald | → $8 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 2023 年 12 月 10 日 | 96.72% | 坎託·菲茨傑拉德 | → 54 美元 | 重申 | 超重 → 超重 |
| 09/27/2023 | 96.72% | 坎託·菲茨傑拉德 | → 54 美元 | 重申 | 超重 → 超重 |
| 08/22/2023 | -23.5% | 富國銀行 | → 21 美元 | 啓動覆蓋範圍開啓 | → 體重不足 |
| 08/16/2023 | 96.72% | 坎託·菲茨傑拉德 | → 54 美元 | 重申 | 超重 → 超重 |
| 08/10/2023 | 165.94% | HC Wainwright & Co. | → 73 美元 | 重申 | 購買 → 購買 |
| 08/09/2023 | 165.94% | HC Wainwright & Co. | → 73 美元 | 重申 | 購買 → 購買 |
| 06/12/2023 | 165.94% | HC Wainwright & Co. | → 73 美元 | 重申 | 購買 → 購買 |
| 05/31/2023 | 165.94% | HC Wainwright & Co. | → 73 美元 | 重申 | → 購買 |
| 05/05/2023 | 96.72% | 坎託·菲茨傑拉德 | 55 美元 → 54 美元 | 維護 | 超重 |
| 05/05/2023 | 165.94% | HC Wainwright & Co. | → 73 美元 | 重申 | → 購買 |
| 03/22/2023 | 165.94% | HC Wainwright & Co. | → 73 美元 | 重申 | → 購買 |
| 03/01/2023 | 165.94% | HC Wainwright & Co. | → 73 美元 | 重申 | → 購買 |
| 02/27/2023 | 165.94% | HC Wainwright & Co. | → 73 美元 | 重申 | → 購買 |
| 11/11/2022 | 129.51% | 古根海姆 | 68 美元 → 63 美元 | 維護 | 購買 |
| 08/09/2022 | 133.15% | SVB Leerink | 68 美元 → 64 美元 | 維護 | 跑贏大盤 |
| 2022 年 1 月 7 日 | 165.94% | HC Wainwright & Co. | 60 美元 → 73 美元 | 維護 | 購買 |
| 09/17/2021 | 140.44% | 傑富瑞 | → 66 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 09/13/2021 | 118.58% | HC Wainwright & Co. | 54 美元 → 60 美元 | 維護 | 購買 |
| 2021 年 10 月 9 日 | 147.72% | SVB Leerink | → 68 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2021 年 6 月 8 日 | 96.72% | HC Wainwright & Co. | 50 美元 → 54 美元 | 維護 | 購買 |
| 07/22/2021 | 140.44% | 古根海姆 | → 66 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 07/12/2021 | 82.15% | HC Wainwright & Co. | 36 美元 → 50 美元 | 維護 | 購買 |
| 2021 年 2 月 23 日 | 31.15% | HC Wainwright & Co. | 25 美元 → 36 美元 | 維護 | 購買 |
| 2020 年 10 月 19 日 | -8.93% | HC Wainwright & Co. | 16 美元 → 25 美元 | 維護 | 購買 |
| 03/27/2020 | -41.71% | HC Wainwright & Co. | 19 美元 → 16 美元 | 重申 | → 購買 |
| 02/21/2020 | -70.86% | 坎託·菲茨傑拉德 | → 8 美元 | 啓動覆蓋範圍開啓 | → 超重 |
What is the target price for Celldex Therapeutics (CLDX)?
Celldex Therapeutics（CLDX）的目標價格是多少？
The latest price target for Celldex Therapeutics (NASDAQ: CLDX) was reported by Cantor Fitzgerald on October 12, 2023. The analyst firm set a price target for $54.00 expecting CLDX to rise to within 12 months (a possible 96.72% upside). 14 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2023年10月12日公佈了Celldex Therapeutics（納斯達克股票代碼：CLDX）的最新目標股價。該分析公司將目標股價定爲54.00美元，預計CLDX將在12個月內上漲至96.72％（可能上漲96.72％）。去年有14家分析公司公佈了評級。
What is the most recent analyst rating for Celldex Therapeutics (CLDX)?
分析師對Celldex Therapeutics（CLDX）的最新評級是多少？
The latest analyst rating for Celldex Therapeutics (NASDAQ: CLDX) was provided by Cantor Fitzgerald, and Celldex Therapeutics reiterated their overweight rating.
Celldex Therapeutics（納斯達克股票代碼：CLDX）的最新分析師評級由坎託·菲茨傑拉德提供，Celldex Therapeutics重申了其增持評級。
When is the next analyst rating going to be posted or updated for Celldex Therapeutics (CLDX)?
Celldex Therapeutics（CLDX）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Celldex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Celldex Therapeutics was filed on October 12, 2023 so you should expect the next rating to be made available sometime around October 12, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與Celldex Therapeutics的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Celldex Therapeutics的最後一次評級是在2023年10月12日提交的，因此你應該預計下一個評級將在2024年10月12日左右公佈。
Is the Analyst Rating Celldex Therapeutics (CLDX) correct?
分析師對 Celldex Therapeutics (CLDX) 的評級正確嗎？
While ratings are subjective and will change, the latest Celldex Therapeutics (CLDX) rating was a reiterated with a price target of $0.00 to $54.00. The current price Celldex Therapeutics (CLDX) is trading at is $27.45, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的Celldex Therapeutics（CLDX）評級，目標股價爲0.00美元至54.00美元。Celldex Therapeutics（CLDX）目前的交易價格爲27.45美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。